Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor

By Kallas A.   Pooga M.   Benhida A.   Jacquemin M.   Saint-Remy J.-M.  

Thrombosis Research, Vol. 107, Iss. 6, 2002-09 ,pp. : 291-302

Elsevier

Access to resources Recommend Favorite

Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5

By Chang Y.-J.   Wu H.-L.   Hsu Y.-C.   Hamaguchi N.   Shi G.-Y.   Shen M.-C.   Lin S.-W.  

Thrombosis Research, Vol. 111, Iss. 4, 2003-01 ,pp. : 293-299

Elsevier

Access to resources Recommend Favorite

In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic

By Scandella D.H.   Nakai H.   Felch M.   Mondorf W.   Scharrer I.   Hoyer L.W.   Saenko E.L.  

Thrombosis Research, Vol. 101, Iss. 5, 2001-03 ,pp. : 377-385

Elsevier

Access to resources Recommend Favorite

Effects of chemical modifiers on recombinant factor VIII activity

By Manning F.   Fagain C.O.   O'Kennedy R.   Woodhams B.  

Thrombosis Research, Vol. 80, Iss. 3, 1995-11 ,pp. : 247-254

Elsevier

Access to resources Recommend Favorite

Factor VIII is a positive regulator of platelet function

By Obergfell A.   Sturm A.   Speer C. P.   Walter U.   Grossmann R.  

Platelets, Vol. 17, Iss. 7, 2006-11 ,pp. : 448-453

Informa Healthcare

Access to resources Recommend Favorite